Quick Answer
Prelude Therapeutics Inc reported Revenue (ASC 606) of $12.14 million for fiscal year 2025.
Prelude Therapeutics Inc Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $12.14M | +73.4% |
| 2024 | $7.00M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.50M | +116.7% | +116.7% |
| September 30, 2024 | $3.00M | — | — |
- Prelude Therapeutics Inc showed an increase of +73.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2024–2025 period, Prelude Therapeutics Inc’s revenue (asc 606) has grown by 73.4% (from $7.00 million to $12.14 million).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: